Azurrx Biopharma Inc
NASDAQ:AZRX (9/21/2021, 7:00:01 PM)
After market: 3.42 -0.03 (-0.87%)3.45
+0.07 (+2.07%)
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
Azurrx Biopharma Inc
1615 SOUTH CONGRESS AVENUE, SUITE 103
Delray Beach FLORIDA 33445
P: 16466997855.0
CEO: James Sapirstein
Employees: 12
Website: https://www.azurrx.com/
Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration
Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
Here you can normally see the latest stock twits on AZRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: